CT SB00188 | 2022 | General Assembly
Status
Spectrum: Slight Partisan Bill (Democrat 3-1)
Status: Introduced on February 24 2022 - 25% progression, died in committee
Action: 2022-04-07 - Referred by Senate to Committee on Judiciary
Pending: Joint Judiciary Committee
Text: Latest bill text (Comm Sub) [PDF]
Status: Introduced on February 24 2022 - 25% progression, died in committee
Action: 2022-04-07 - Referred by Senate to Committee on Judiciary
Pending: Joint Judiciary Committee
Text: Latest bill text (Comm Sub) [PDF]
Summary
To promote competition in the prescription drug market by allowing developers of generic drugs and biosimilar products to obtain reference samples.
Title
An Act Requiring Brand Name Prescription Drug Manufacturers To Provide Samples Of Brand Name Drugs To Generic Prescription Drug Manufacturers.
Sponsors
Roll Calls
2022-03-15 - Joint - GL Vote Tally Sheet (Joint Favorable) (Y: 11 N: 7 NV: 0 Abs: 1) [PASS]
History
| Date | Chamber | Action |
|---|---|---|
| 2022-04-07 | Senate | Referred by Senate to Committee on Judiciary |
| 2022-03-30 | Senate | File Number 214 |
| 2022-03-30 | Senate | Senate Calendar Number 170 |
| 2022-03-30 | Senate | Favorable Report, Tabled for the Calendar, Senate |
| 2022-03-30 | Senate | Reported Out of Legislative Commissioners' Office |
| 2022-03-24 | Senate | Referred to Office of Legislative Research and Office of Fiscal Analysis 03/29/22 5:00 PM |
| 2022-03-16 | Senate | Filed with Legislative Commissioners' Office |
| 2022-03-15 | Senate | Joint Favorable |
| 2022-02-25 | Senate | Public Hearing 03/01 |
| 2022-02-24 | Senate | Referred to Joint Committee on General Law |
